{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:31:18Z","timestamp":1772559078683,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.nucmedbio.2025.109601","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:43:55Z","timestamp":1766475835000},"page":"109601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rodent biodistribution and dosimetry of the PET radioligands [18F]CHDI-385 and [18F]CHDI-386 targeting mutant huntingtin aggregates"],"prefix":"10.1016","volume":"152-153","author":[{"given":"Jordy","family":"Akkermans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipe","family":"Elvas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Zajicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Bard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Khetarpal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Doot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Staelens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Bertoglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2025.109601_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Group THsDCR","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0015","doi-asserted-by":"crossref","first-page":"eabm3682","DOI":"10.1126\/scitranslmed.abm3682","article-title":"Development of a ligand for in vivo imaging of mutant huntingtin in Huntington\u2019s disease","volume":"14","author":"Bertoglio","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0020","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s00259-021-05578-8","article-title":"Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington\u2019s disease","volume":"49","author":"Bertoglio","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0025","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2967\/jnumed.123.265569","article-title":"In vivo cerebral imaging of mutant huntingtin aggregates using 11C-CHDI-180R PET in a nonhuman primate model of Huntington disease","volume":"64","author":"Bertoglio","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0030","doi-asserted-by":"crossref","first-page":"17977","DOI":"10.1038\/s41598-021-97334-z","article-title":"Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates","volume":"11","author":"Herrmann","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0035","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1021\/acs.jmedchem.1c00667","article-title":"[11C]CHDI-626, a PET tracer candidate for imaging mutant huntingtin aggregates with reduced binding to AD pathological proteins","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0040","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1021\/acs.jmedchem.0c00955","article-title":"Imaging mutant huntingtin aggregates: development of a potential PET ligand","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00259-022-05945-z","article-title":"Biodistribution and dosimetry in human healthy volunteers of the PET radioligands [11C]CHDI-00485180-R and [11C]CHDI-00485626, designed for quantification of cerebral aggregated mutant huntingtin","volume":"50","author":"Delva","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0050","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jfluchem.2006.09.015","article-title":"Fluorine-18 and medical imaging: radiopharmaceuticals for positron emission tomography","volume":"127","author":"Le Bars","year":"2006","journal-title":"J Fluor Chem"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0055","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1021\/acs.jmedchem.2c01585","article-title":"Design and evaluation of [18F]CHDI-650 as a positron emission tomography ligand to image mutant huntingtin aggregates","volume":"66","author":"Liu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-024-06880-x","article-title":"Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington\u2019s disease","volume":"52","author":"Zajicek","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13550-024-01188-1","article-title":"Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregates","volume":"14","author":"Akkermans","year":"2024","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0070","doi-asserted-by":"crossref","first-page":"14818","DOI":"10.1021\/acs.jmedchem.5c01005","article-title":"Isoindolinone-based PET tracers for imaging mutant huntingtin aggregates","volume":"68","author":"Liu","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0075","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.125.270660","article-title":"In vivo PET imaging of [18F]CHDI-385, a radioligand for mutant huntingtin aggregates in a mouse model of Huntington disease","author":"Zajicek","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0080","doi-asserted-by":"crossref","DOI":"10.1088\/2057-1976\/ab8c13","article-title":"Validation of a spatially variant resolution model for small animal brain PET studies","volume":"6","author":"Miranda","year":"2020","journal-title":"Biomed Phys Eng Express"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0085","series-title":"Adult reference computational phantoms","volume":"vol. 110","author":"ICRP","year":"2009"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40658-020-00326-7","article-title":"Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice","volume":"7","author":"Ukon","year":"2020","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0095","first-page":"247","article-title":"Radiation dosimetry of 131I-19-iodocholesterol: the pitfalls of using tissue concentration data","volume":"16","author":"Blau","year":"1975","journal-title":"J Nucl Med"},{"issue":"32","key":"10.1016\/j.nucmedbio.2025.109601_bb0100","first-page":"1","article-title":"Basic anatomical and physiological data for use in radiological protection","volume":"89","author":"ICRP","year":"2002","journal-title":"ICRP Publ"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0105","first-page":"585","article-title":"OLINDA\/EXM 2.0: the new generation dosimetry modeling code","volume":"53","author":"Stabin","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","author":"Andersson","year":"2017","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0115","series-title":"The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103","first-page":"1","volume":"vol. 37","author":"ICRP","year":"2007"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0120","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","article-title":"Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies","volume":"40","author":"Zanotti-Fregonara","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11307-016-0992-3","article-title":"Radiation dosimetry of a novel adenosine A2A receptor radioligand [11C]Preladenant based on PET\/CT imaging and ex vivo biodistribution in rats","volume":"19","author":"Zhou","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0130","series-title":"Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research","author":"United States Federal Regulations for Radioactive Drugs for Certain Research Uses (21CFR361.1)","year":"2023"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0135","series-title":"Guidance on medical exposures in medical and biomedical research","author":"European Commission","year":"1998"},{"key":"10.1016\/j.nucmedbio.2025.109601_bb0140","series-title":"Radiological protection in biomedical research. ICRP publication 62","volume":"vol. 22","author":"ICRP","year":"1992"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125006109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805125006109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:20:00Z","timestamp":1772554800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805125006109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"alternative-id":["S0969805125006109"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109601","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rodent biodistribution and dosimetry of the PET radioligands [18F]CHDI-385 and [18F]CHDI-386 targeting mutant huntingtin aggregates","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2025.109601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109601"}}